Latest Breaking News On - Clin pract - Page 2 : comparemela.com

European Medicines Agency Validates Type II Variation for Astellas XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

European Medicines Agency Validates Type II Variation for Astellas XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

United statesAhsan arozullahNaoki okamuraDrug administrationMedivation incAstellas pharma incEuropean unionAmerican society of clinical oncologyHead of oncology developmentAstellas incAmerican urological association annual meeting onEuropean medicines agencyEuropean medicines agency validates typeNon metastatic hormone sensitive prostate cancerHigh risk biochemicalSenior vice president

European Medicines Agency Validates Type II Variation for Astellas XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the European Medicines Agency (EMA) has.

United statesAhsan arozullahNaoki okamuraMedivation incDrug administrationEuropean unionPrnewswire astellas pharma incAmerican urological association annual meeting onAmerican society of clinical oncologyHead of oncology developmentEuropean medicines agencyAstellas pharma incAstellas incSenior vice presidentOncology developmentUrological association annual meeting

FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

/PRNewswire/ Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food.

United statesChris boshoffAhsan arozullahNaoki okamuraPrnewswire pfizer incAstellas incExchange commissionHead of oncology developmentAstellas pharma incEuropean unionAmerican society of clinical oncologyDrug administrationOncology researchLab abnormalitiesMedivation incAstellas pharma

Neurologic Events After COVID-19 Vaccines Assessed

Study finds preexisting risk factors in all patients hospitalized for neurologic symptoms

New yorkUnited statesKiran thakurJudy georgeColumbia university irving medical center newyorkColumbia university irving medicalNewyork presbyterian hospitalNew york cityVaccine adverse event reporting systemVaccine safety datalinkMedpage todayClin pract

XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) announced today that XTANDI®.

United statesNaoki okamuraExchange commissionMedivation incLab abnormalitiesEuropean unionAstellas incPfizer incAmerican society of clinical oncologyAstellas pharma incPrnewswire astellas pharma incAmerican urological association annual meetingUrological association annualHazard ratioConfidence intervalPfizer led phase